Company Profile (AI Text)
Name: Ventoux Biosciences
Canonical URL: https://wefunder.com/ventoux.biosciences
Updated at: 2026-07-21T23:54:16Z

Tagline: Modulating Fibrosis, Restoring Function 

Key claims:
- Total raised on Wefunder: 0 | citation: https://wefunder.com/ventoux.biosciences#claim-total-raised
- Total investors: 0 | citation: https://wefunder.com/ventoux.biosciences#claim-total-investors

Verified facts:
- Total raised on Wefunder: 0 | observed_at: 2026-07-21T23:54:16Z | expires_at: 2026-07-22T23:54:16Z
- Total investors: 0 | observed_at: 2026-07-21T23:54:16Z | expires_at: 2026-07-22T23:54:16Z

Computed metrics:
- total_amount_raised: 0
- total_investors: 0
- team_size: 3
- featured_investor_count: 1
- faq_count: 0
- recent_post_count: 0

Quick facts:
- Founded by a Dupuytren's patient to transform care for millions with immune-fibrotic diseases | citation: https://wefunder.com/ventoux.biosciences#claim-fact-1
- Targeting Dupuytren's and Spinal Cord Injury with VEN-201, a novel, immune-fibrotic modulator | citation: https://wefunder.com/ventoux.biosciences#claim-fact-2
- VEN-201 rebalances the immune system to reduce fibrosis and activate repair | citation: https://wefunder.com/ventoux.biosciences#claim-fact-3
- 2025 Pre-Clinical Biopharmaceutical Company of the Year Winner, by GHP Biotechnology Awards | citation: https://wefunder.com/ventoux.biosciences#claim-fact-4
- $4.3B Dupuytren's disease market, >3x larger than Rheumatoid Arthritis - no approved treatments | citation: https://wefunder.com/ventoux.biosciences#claim-fact-5
- SCI: ~$10B annually, VEN-201 targets fibrosis, addressing the key market opportunity in recovery | citation: https://wefunder.com/ventoux.biosciences#claim-fact-6
- Strong IP: Broad immune-fibrotic patent to 2044, global filings plus key provisional filings | citation: https://wefunder.com/ventoux.biosciences#claim-fact-7